According to a new market research report published by sheer analytics and insights, “The Global Implantable Neurostimulators Market was $4.92 Bn in 2020, and it is expected to reach $13.4 Bn by 2031. It is eventually growing at a commendable high compound annual growth rate CAGR of 9.3% between 2021-2031”, as per the latest market research report titled Global Implantable Neurostimulators Market - Industry analysis, size, share, growth, trends and forecast, 2021 – 2031.
Increased cases of chronic disorders like movement disorders, epilepsy, chronic pain, depression, Parkinson’s disease, and also the advancements in the minimally invasive neurosurgical procedures will help to accelerate the growth of this market during the forecasted period. Neurostimulation therapy is used for the diagnosis and treatments of many disorders that is linked with the nervous systems. It even helps to reduce the chronic pain and symptoms that is associated with the Parkinson’s disease and epilepsy. So this will help in the growth of this market during the forecasted period.
Geographically, The Global Implantable Neurostimulators Market is divided into global regions like North America, Europe, Asia- Pacific, Latin America, Middle East, and Africa.
The primary key players in Global Implantable Neurostimulators Market include Abbott (St. Jude Medical), Medtronic, Boston Scientific Corporation, Aleva Neurotherapeutics SA, Synapse Biomedical Inc., Nevro Corp., LivaNova PLC, NeuroPace, Inc., Beijing Pins, Synapse Biomedical.
The Global Implantable Neurostimulators Market Has Been Segmented Into:
Global Implantable Neurostimulators Market, By Type
Global Implantable Neurostimulators Market, By Application
Global Implantable Neurostimulators Market, By Region